Systematic Review
Accepted on 07 May 2026
Efficacy and Safety of BCMA-or GPRC5D-Directed CD3 Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma: A Systematic Review and Meta-Analysis of Prospective Clinical Trials and Real-World Studies
in Cancer Immunity and Immunotherapy